Method for treating obesity

• US 7,109,198 B2
• Filed: 05/19/2003
• Issued: 09/19/2006
• Est. Priority Date: 05/17/2002
• Status: Active Grant

• Current Assignee: Duke University
• Original Assignee: Duke University
• Inventors: Gadde, Kishore M., Krishnan, K. Ranga R.
• Primary Examiner(s): JONES, DWAYNE C
• Application Number:
  US10/440,404
• Publication Number:
  US 20040033965A1
• Time in Patent Office: 1,219 Days
• Field of Search: 514/439, 514/455, 514/459, 514/463
• US Class Current: 514/238.8
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/255 of sulfoxy acids or sulfur analogues thereof
• CPC Class Codes: A61K 31/35 having six-membered rings with one oxygen as the only ring hetero atom
• CPC Class Codes: A61K 31/357 having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• CPC Class Codes: A61K 31/42 Oxazoles
• CPC Class Codes: A61K 31/423 condensed with carbocyclic rings
• CPC Class Codes: A61K 31/7024 Esters of saccharides
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/12 Antihypertensives

Abstract

The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.

Claims

1. A method of treating obesity in a mammal comprising administering to a mammal in need of such treatment at least one compound that enhances the activity of norepinephrine and/or dopamine selected from the group consisting of bupropion, atomoxetine, and reboxetine, and at least one weight-loss promoting anticonvulsant wherein said anticonvulsant is of formula (III):

2. The method according to claim 1 wherein said anticonvulsant is zonisamide.

3. The method according to claim 1 wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion.

4. The method according to claim 1 wherein said anticonvulsant and said compound that enhances the activity of norepinephrine and/or dopamine are administered separately.

5. The method according to claim 1 wherein said anticonvulsant and said compound that enhances the activity of norepinephrine and/or dopamine are administered concurrently.

9. The composition according to claim 1 wherein said composition is in the form of a tablet or capsule.

6. A method of reducing the risk of hypertension, diabetes or dyslipidaemia in a mammal comprising administering to a mammal in need of such reduction at least one compound that enhances the activity of norepinephrine and/or dopamine selected from the group consisting of bupropion, atomoxetine, and reboxetine, and at least one weight-loss promoting anticonvulsant according to formula (III) in amounts such that said reduction is effected, where formula (III) is:

7. A composition comprising at least one compound that enhances the activity of norepinephrine and/or dopamine selected from the group consisting of bupropion, atomoxetine, and reboxetine, and at least one weight-loss promoting anticonvulsant of formula (III):

8. The composition according to claim 7 wherein said compound is in dosage unit form.

10. The composition according to claim 7 wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion and said anticonvulsant is zonisamide.

11. The composition according to claim 7 wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion.